Inclusion criteria were diagnosis of peripheral neuropathy, neuropathic pain (visual analog scale > 4) for at least 6 months, and stable analgesic medications for at least 3 months.
Patients. Sixteen patients were randomized into two arms to be
treated with EA or pseudo-EA (placebo).
Interventions. The protocol included 6 weeks of treatment, 12 weeks free of treatment, and then further 6 weeks of treatment. EA or pseudo-EA was performed weekly during each treatment period.
Outcome Measures. The primary outcome was ON-01910 in vitro the number of patients treated with EA achieving at least 50% of pain relief at the end of each treatment compared with pain intensity at baseline. Secondary outcomes were modification in patient’s global impression of change, depression and anxiety, and quality of life.
Results.
Eleven patients were randomized to EA and five patients to pseudo-EA as the first treatment.
Only one patient per group (EA and pseudo-EA) reported 50% of pain relief at the end of each treatment compared with pain intensity at baseline. Pain intensity did not differ between EA (5.7 +/- 2.3 at baseline and 4.97 +/- 3.23 after treatment) and pseudo-EA (4.9 +/- 1.9 at baseline and 4.18 +/- 2.69 after treatment). There was no difference between patients who received EA as the first treatment and patients initially treated with placebo. There was no change in the secondary outcomes.
Conclusions. Our results do not support the use of EA in this population of painful neuropathy patients. Further studies in larger groups of patients are warranted to confirm our observation.”
“BACKGROUND click here During Mohs surgery, there are instances in which residual tumor cells may be difficult to detect, thereby increasing the risk of incomplete excision and tumor recurrence. It is possible to employ immunohistochemical techniques as an adjunct to routine hematoxylin and eosin staining to aid in ensuring negative margins.
OBJECTIVE To review the literature regarding the use of immunostains in Mohs surgery.
RESULTS Various immunostains have proved useful in detecting tumor cells
in various malignancies, including melanoma, Selleck PF-6463922 basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, extramammary Paget’s disease, primary cutaneous mucinous carcinoma, granular cell tumor, and trichilemmal carcinoma.
CONCLUSIONS In this article, we review immunohistochemical stains that have been employed in Mohs micrographic surgery and evaluate their utility in enhancing detection of residual tumors with respect to tumor type, particularly in situations in which detection of residual tumor may be difficult.”
“Objective: To confirm effectiveness of nonsurgical periodontal treatment during pregnancy on pregnancy outcome in terms of preterm birth and low birth weight (LBW).
Method: We searched for Randomized controlled trials in MEDLINE, CINAHL and EMBASE. from January 2000 to October 2012.